Patients often describe feeling unusually tired, low on motivation, or physically sluggish during the early weeks of treatment
Deyu Li, Dr
Publicly funded research agencies like the National Institutes of Health could play an important role by rapidly investigating the most promising uses of GLP-1 drugs, particularly in areas where pharmaceutical companies may be reluctant to invest, such as traumatic brain injury, for which trials are difficult to run
Lab tests: Occasionally, they might check labs like your liver enzymes, pancreatic enzymes (amylase/lipase) if theres any concern about pancreatitis, and maybe lipid profile or vitamin levels after some time
Tolerability and safety were assessed concurrently: adverse events (AEs) were solicited at each visit and recorded
To answer this, we have to understand how the drug works